Efficacy of Potassium-Competitive Acid Blockers in Barrett's Esophagus (PCAB BE Study)

This is a research study to look at how a new medication compares to standard treatment for reducing acid reflux in patients with Barrett's Esophagus. The study drug is Vonoprazan. This is a pill that is not yet FDA-approved for this purpose in this patient population. The participants will first continue their current acid-reducing medicine (PPI) once a day for at least 7 days. After that, they will have a test to measure acid levels in their esophagus (food tube) while still taking the PPI medication. After this test, they will stop their current PPI medication and start taking the study dr

Trial Details

NCT ID
NCT07788742
Phase
PHASE4
Sponsor
University of North Carolina, Chapel Hill
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Potassium-Competitive Acid Blockers (PCABs)
Locations (sample)
  • Chapel Hill, North Carolina, United States|35.9132,-79.05584

Key Eligibility Criteria

  • Adults aged 18 or older at time of consent.
  • Able to read and understand English and provide written informed consent.
  • History of Gastroesophageal Reflux Disease (GERD) with or without heartburn.
  • Diagnosed with nondysplastic Barrett's Esophagus (NBDE) defined as meeting the following within the past 3 years:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →